Across TCGA pan-cancer cohorts, MAGI2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAGI2 data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAGI2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAGI2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where MAGI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.187	0.797	.001	52	view →
CCRCC	OS	Median	All	1.000	0.585	.003	18	view →
PDAC	OS	Median	All	0.822	0.358	.025	6	view →
LSCC	DFS	Tertile	All	1.000	0.917	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MAGI2 tumor-vs-normal RNA expression · all MAGI2 data types